


has the phase transitions I / N* 95.1-92.1 and N* / Sc* 64.6°C and the values DT (15,1) / DT (20,1) / DT (25,1) / DT (30,1) 35 / 40 / 35.5 / 31.5.

5 Example 15

A mixture consisting of 85% of the mixture of Example 5 and 15% of the compound



10


has the phase transitions I / N* 99.6-96.0 and N* / Sc* 63.2°C and the values DT (15,1) / DT (20,1) / DT (25,1) / DT (30,1) 32.5 / 30 / 28.8 / 26.

The compounds according to the invention are further illustrated by Examples 16-25.

15

Example 16

4-(2-Fluoro-3-hexyloxypryridine6-yl)phenyl 5-octylthiophene-2-carboxylate



20

0.8 g of 4-(2-fluoro-3-hexyloxypryridine-6-yl)phenol and 0.7 g 5-octylthiophene-2-carboxylic acid are reacted in 100 ml of dichloromethane in the presence of 0.6 g of dicyclohexylcarbodiimide. Workup by filtration, column chromatography and recrystallization gives 1 g of colorless crystals having a melting point of 101°C and a clearing point of 124°C.

25


The following compounds are obtained in a similar manner:

Example 17

4-(2-Fluoro-3-hexyloxyphenyl)phenyl 5-hexylthiophene-2-carboxylate
having a melting point of 95°C and a clearing point of 126°C.

5 Example 18

6-(4-Octyloxyphenyl)-2-fluoropyridin-3-yl 5-butylthiophene-2-carboxylate




having a melting point of 86°C and a clearing point of 114°C.

10

Example 19


4-(5-Decyl-4-fluoropyrimidin-2-yl)phenyl 5-butylthiophene-2-carboxylate



15

Example 20

4-(6-Ethyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate



20

Phase sequence X 114 N 216 I

Example 21

4-(6-Nonyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

25

Phase sequence X 112 S_C 124 S_A 143 N 204 I

Example 22

4-(6-Nonyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-propylcyclohexanecarboxylate

Phase sequence X 111 (S_C 100) S_A 124 N 202 I

5

Example 23

4-(6-Propyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

Phase sequence X 99 N 175 I

10

Example 24

4-(6-Hexyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

Phase sequence X 100 N 155

15

Example 25

4-(6-Octyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

Phase sequence X 97 (S_C95) N 145 I

20

Example 26

4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

Phase sequence X 555₂ 96 S_C 130 N 151 I

25

Example 27

4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-hexylcyclohexanecarboxylate

Phase sequence X 77 S₂ 105 S_C 133 N 147 I

Example 28

30 4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-heptylcyclohexanecarboxylate

Phase sequence X 41 S₂ 108 S_C 136 N 148 I

Example 29

2-(4-Undecylphenyl)pyrimidin-5-yl trans-4-propylcyclohexanecarboxylate

35 Phase sequence X 77 S_A 165 N 171 I